ANIK
Price
$10.08
Change
-$0.02 (-0.20%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
145.51M
116 days until earnings call
Intraday BUY SELL Signals
ORGO
Price
$6.21
Change
-$0.27 (-4.17%)
Updated
Nov 13 closing price
Capitalization
789.39M
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANIK vs ORGO

Header iconANIK vs ORGO Comparison
Open Charts ANIK vs ORGOBanner chart's image
Anika Therapeutics
Price$10.08
Change-$0.02 (-0.20%)
Volume$2.42K
Capitalization145.51M
Organogenesis Holdings
Price$6.21
Change-$0.27 (-4.17%)
Volume$1.08M
Capitalization789.39M
ANIK vs ORGO Comparison Chart in %
ANIK
Daily Signal:
Gain/Loss:
ORGO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ANIK vs. ORGO commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a Buy and ORGO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ANIK: $10.10 vs. ORGO: $6.48)
Brand notoriety: ANIK and ORGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ANIK: 98% vs. ORGO: 89%
Market capitalization -- ANIK: $145.51M vs. ORGO: $789.39M
ANIK [@Pharmaceuticals: Generic] is valued at $145.51M. ORGO’s [@Pharmaceuticals: Generic] market capitalization is $789.39M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANIK’s FA Score shows that 0 FA rating(s) are green whileORGO’s FA Score has 1 green FA rating(s).

  • ANIK’s FA Score: 0 green, 5 red.
  • ORGO’s FA Score: 1 green, 4 red.
According to our system of comparison, ORGO is a better buy in the long-term than ANIK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANIK’s TA Score shows that 5 TA indicator(s) are bullish while ORGO’s TA Score has 5 bullish TA indicator(s).

  • ANIK’s TA Score: 5 bullish, 2 bearish.
  • ORGO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ANIK is a better buy in the short-term than ORGO.

Price Growth

ANIK (@Pharmaceuticals: Generic) experienced а +2.54% price change this week, while ORGO (@Pharmaceuticals: Generic) price change was +63.22% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

ANIK is expected to report earnings on Mar 10, 2026.

ORGO is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORGO($789M) has a higher market cap than ANIK($146M). ORGO has higher P/E ratio than ANIK: ORGO (63.75) vs ANIK (10.71). ORGO YTD gains are higher at: 102.500 vs. ANIK (-38.639). ORGO has higher annual earnings (EBITDA): 3.19M vs. ANIK (-2.24M). ORGO has more cash in the bank: 73.1M vs. ANIK (53.2M). ANIK has less debt than ORGO: ANIK (25M) vs ORGO (40.8M). ORGO has higher revenues than ANIK: ORGO (429M) vs ANIK (115M).
ANIKORGOANIK / ORGO
Capitalization146M789M19%
EBITDA-2.24M3.19M-70%
Gain YTD-38.639102.500-38%
P/E Ratio10.7163.7517%
Revenue115M429M27%
Total Cash53.2M73.1M73%
Total Debt25M40.8M61%
FUNDAMENTALS RATINGS
ANIK vs ORGO: Fundamental Ratings
ANIK
ORGO
OUTLOOK RATING
1..100
2430
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
10091
SMR RATING
1..100
9693
PRICE GROWTH RATING
1..100
5735
P/E GROWTH RATING
1..100
1009
SEASONALITY SCORE
1..100
n/a65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORGO's Valuation (73) in the Financial Conglomerates industry is in the same range as ANIK (89) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.

ORGO's Profit vs Risk Rating (91) in the Financial Conglomerates industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.

ORGO's SMR Rating (93) in the Financial Conglomerates industry is in the same range as ANIK (96) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.

ORGO's Price Growth Rating (35) in the Financial Conglomerates industry is in the same range as ANIK (57) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew similarly to ANIK’s over the last 12 months.

ORGO's P/E Growth Rating (9) in the Financial Conglomerates industry is significantly better than the same rating for ANIK (100) in the Pharmaceuticals Other industry. This means that ORGO’s stock grew significantly faster than ANIK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANIKORGO
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ANIK
Daily Signal:
Gain/Loss:
ORGO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFALX34.310.24
+0.70%
DFA Large Cap International I
EAEMX17.700.05
+0.28%
Parametric Emerging Markets A
IEGFX23.340.05
+0.21%
Invesco International Small Company R6
AMRAX7.250.01
+0.14%
American Growth One A
DIFGX12.53-0.01
-0.08%
MFS Diversified Income R4

ANIK and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANIK has been loosely correlated with RVTY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIK jumps, then RVTY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANIK
1D Price
Change %
ANIK100%
-0.30%
RVTY - ANIK
39%
Loosely correlated
-0.19%
AVNS - ANIK
35%
Loosely correlated
+0.86%
ORGO - ANIK
35%
Loosely correlated
-0.31%
ACRS - ANIK
34%
Loosely correlated
+4.78%
FLGT - ANIK
32%
Poorly correlated
+2.47%
More

ORGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORGO has been loosely correlated with ANIP. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ORGO jumps, then ANIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
-0.31%
ANIP - ORGO
45%
Loosely correlated
-1.43%
ANIK - ORGO
36%
Loosely correlated
-0.30%
PRGO - ORGO
34%
Loosely correlated
-0.98%
ACET - ORGO
29%
Poorly correlated
+6.24%
AMPH - ORGO
27%
Poorly correlated
+2.47%
More